Arcturus Therapeutics Secures $50 Million Meiji Investment At 80% Premium

Arcturus Therapeutics has expanded its collaboration with Meiji Seika Pharma through a $50 million equity investment, an additional technology license and a proposed pandemic preparedness partnership in Japan.

Meiji will purchase unregistered Arcturus securities at $20.27 per share, an 80% premium under the announced transaction terms. Its investment will represent approximately 7.9% of outstanding shares following the transaction.

The companies also signed an exclusive license covering the application of Arcturus’s ARCT-154 technology in an undisclosed therapeutic area.

Separately, a memorandum of understanding establishes principal terms for a potential collaboration and license agreement involving pandemic preparedness and response in Japan. That arrangement remains subject to a definitive agreement.

Arcturus intends to use the investment to support its cystic fibrosis program and accelerate ARCT-2601, an investigational treatment for ornithine transcarbamylase deficiency.

ARCT-2601 is the first mRNA therapeutic intended to use the company’s LUNAR 2.0 delivery platform. Its development is expected to contribute to clinical evaluation of that next-generation technology.

President and CEO Joseph Payne said the expanded relationship reflects Meiji’s confidence in the company’s capabilities and platform.

Founded in 2013 and based in San Diego, Arcturus develops mRNA medicines focused on liver and respiratory diseases.

Its technologies include lipid-mediated delivery and self-amplifying RNA. The company also developed KOSTAIVE, a self-amplifying mRNA COVID vaccine.

Other collaborations include work with Thermo Fisher Scientific, BARDA and Japanese manufacturing joint venture ARCALIS.

Meiji’s investment adds capital while extending an existing strategic relationship across development, licensing and potential public-health applications.

The company’s pipeline programs remain subject to clinical development, regulatory review and other requirements before potential commercialization.

KEY QUOTES

“We are pleased to expand our relationship with Meiji as we advance innovative mRNA medicines and seek to deliver value to patients. The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform. Alongside our CF program, these proceeds will be used to accelerate development of ARCT-2601 for OTC deficiency, the first mRNA therapeutic to utilize our LUNAR 2.0 delivery platform.”

Joseph Payne, President And CEO Of Arcturus Therapeutics